Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)

Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)

Background People with schizophrenia die almost 20 years earlier than the general population, most commonly from avertable cardiometabolic disease. Existing pharmacological weight-loss agents including metformin have limited efficacy. Recently available glucagon-like peptide (GLP-1) receptor agonis...

Full description

Bibliographic Details
Main Authors: Dan Siskind, Andrea Baker, Anthony Russell, Nicola Warren, Gail Robinson, Stephen Parker, Sarah Medland, Steve Kisely, Tineka Hager, Urska Arnautovska
Format: Article
Language:English
Published: Cambridge University Press 2023-07-01
Series:BJPsych Open
Subjects:
Schizophrenia
antipsychotics
randomised controlled trial
weight loss
metabolic health
Online Access:https://www.cambridge.org/core/product/identifier/S205647242300532X/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S205647242300532X/type/journal_article

Similar Items